newsfilter
← Latest News
Business Wire·

Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001

Topline data identifies maximum tolerated dose from Phase IIA multiple ascending dose study as assessed by an independent safety review committee Identified dose is unlikely to require lithium therapeutic drug